Skip to search formSkip to main contentSkip to account menu

TRU 016

Known as: TRU-016 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Immunoglobulin GRecombinant Fusion Proteins

Narrower (1)

otlertuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
2015
2015
Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU‐016) is a novel humanized anti‐CD37… 
2014
2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
SummaryPurpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel… 
2013
2013
Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
2010
2010
Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL
Abstract 56 Background: CD37 is a member of the tetraspanin superfamily of molecules which are implicated in diverse processes… 
2010
2010
TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma
Abstract 3931 Background: CD37 is a 50–55 kDa heavily glycosylated member of the tetraspanin superfamily of molecules. This cell… 
Review
2009
Review
2009
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
TRU-016, under development by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG… 
2009
2009
Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent… 
2009
2009
A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.
3017 Background: CD37 is a tetraspan family member expressed predominantly on normal and transformed B-cells across a wide range… 
2009
2009
A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.
Abstract 3424 Poster Board III-312 Background CD37 is a tetraspanin family member expressed predominantly on normal and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License